Pentixapharm Signs Manufacturing Deal for Yttrium-90 Therapy

Pentixapharm Holding AG has inked a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler SE. As per the agreement, Eckert & Ziegler will produce and supply patient-specific doses of Y90-PentixaTher, Pentixapharm's primary radiotherapeutic agent targeting CXCR4 receptors, for clinical trials.

Y90-PentixaTher focuses on cancer cells exhibiting an abundance of CXCR4 receptors, a marker found in several malignancies including leukemias and solid tumors. This compound uses Yttrium-90, ensuring deeper tissue penetration and effective radiation therapy. Notably, this agreement is confined to the clinical development phase, allowing Pentixapharm strategic flexibility for future scale-up decisions.

The collaboration marks a significant progression in Pentixapharm’s oncology program, supporting advancements in targeted cancer therapies. Industry stakeholders emphasize the critical role of accessible radioisotopes in developing novel radiopharmaceuticals.